Nitza Thomasson
Executive Director, Global Head of Research & Development Servier
Nitza Thomasson is Executive Director and Global Head of R&D Neurology at Servier, where she leads the company’s global neurology research and development strategy with a focus on advancing new therapies for patients living with rare neurological diseases. She brings more than two decades of experience across pharmaceutical R&D, biotechnology, and business development. Prior to rejoining Servier, Nitza co-founded pioneering neuroscience companies BrainEver and GenSight Biologics, held senior leadership roles at Sanofi, Fovea, and Tissium, and founded NTZConsulting, advising biopharma companies on development strategy. She holds a PhD in Neuroscience from Sorbonne University and completed postdoctoral research at Northwestern University.
Seminars
Wednesday 27th January 2027
Panel Discussion: Evaluating the Strengths & Limitations of Genetic, Stem Cell, Small Molecule & RNA-Based Muscle Disease Therapies
3:45 pm
- Examining the use of different modalities to address the underlying drivers of muscle degeneration and guide development decisions
- Debating the practical trade-offs between administration, manufacturing and patient accessibility to understand the implications of each modality
- Sharing cross-modality learnings from clinical and translational programsto identify common barriers to pipeline advancement
Thursday 28th January 2027
From Dystrophin to Function: A Patient-Centered Approach to Drug Development in Becker Muscular Dystrophy
1:30 pm
- Moving beyond protein restoration towards meaningful functional improvement for patients
- Understanding why muscle function is what matters most to patients
- Exploring the clinical development of Sevasemten to reveal the lessons learned for future development of other muscular dystrophies
- Establishing the role of small molecules within an increasingly diversified treatment landscape
